Why human body cannot fight HIV infection? Study results could lead to new drug therapies

July 12, 2012 in HIV & AIDS

University of Washington researchers have made a discovery that sheds light on why the human body is unable to adequately fight off HIV infection.

The work, directed by Dr. Michael Gale, Jr., a professor in the Immunology Department, will be featured in the August print issue of the .

The researchers discovered that the vpu, which is created by HIV during infection, directly interferes with the immune response protein IRF3 to dampen the ability of the immune system to protect against .

"By understanding exactly what HIV does to hamper the innate immune response during early infection, we can develop a clearer picture of how the virus is able to evade immunity to establish a long-term infection," said Dr. Brian Doehle, a and lead author of the article.

The research expanded on an earlier discovery by the Gale lab that HIV directly antagonizes the early in infected cells by impairing IRF3 function.

The new studies found that the vpu specifically binds to the immune protein IRF3 and targets it for destruction, thereby, preventing IRF3 from functioning to trigger an immune response within the infected cell.

The scientists also found that engineered to lack vpu, which is made during infection, did not impair the immune response.

"We have effectively identified a new Achilles heel in the arsenal that HIV uses to overcome the defenses present in the body's immune system", stated Dr. Gale. "This knowledge can be used to design new HIV antiviral therapeutics that prevent vpu from interacting with IRF3 and targeting it for destruction, thus enhancing immunity.

The development of new HIV antiviral therapeutics is critical to successfully treating HIV-infected people. Even though HIV antiviral therapeutics have already been developed and can effectively treat HIV infections, over time they lose their effectiveness due to the ability of the virus to adapt and spread despite the therapy, said Gale. "Therefore, the identification of new targets for treatment therapy is essential to providing the most effective treatment for HIV-infected patients".

Gale's laboratory has already begun translating the knowledge from these discoveries to tracking the molecular events that occur in patients during infection.

Arjun Rustagi, an MD/PhD student in the UW Medical Scientist Training Program, has developed a procedure to measure IRF3 activity in human blood cells. This new methodology will be used to measure IRF3 function over the course of -- from the early stages of acute infection to the later stages of chronic infection that lead to AIDS.

By linking IRF3 function with infection over time, researchers will be able to understand how antiviral therapeutics that are designed to improve IRF3 function might impact the overall course of the disease in an HIV-infected individual.

More information: Details on the development of the new assay will be published in the August 2012 issue of the journal, Methods.

Journal reference: Journal of Virology search and more info website

Provided by University of Washington search and more info website

5 /5 (1 vote)  

Rank 5 /5 (1 vote)
Relevant PhysicsForums posts

More news stories

Fecal microbiota tx feasible for recurrent C. difficile in HIV

(HealthDay)—For HIV-infected individuals with recurrent Clostridium difficile infection, fecal microbiota therapy is feasible, according to a letter published in the May 21 issue of the Annals of Intern ...

HIV & AIDS created 3 hours ago | popularity not rated yet | comments 0

Canada lifts ban on gay men donating blood

Canadian health authorities lifted Wednesday what was effectively a ban on gay men giving blood, announcing new rules making men who have not had sex with men in the past five years eligible.

HIV & AIDS created 5 hours ago | popularity not rated yet | comments 1

AIDS scientists optimistic of AIDS cure, for some

Top AIDS scientists were optimistic Wednesday of finding a cure for the disease that has claimed 30 million lives—but said it might not work for all people.

HIV & AIDS created 8 hours ago | popularity not rated yet | comments 0

Integrating mental health care into HIV care

The integration of mental health interventions into HIV prevention and treatment platforms can reduce the opportunity costs of care and improve treatment outcomes, argues a new Policy Forum article published in this week's ...

HIV & AIDS created May 21, 2013 | popularity not rated yet | comments 0

After a decade, global AIDS program looks ahead

(AP)—The decade-old law that transformed the battle against HIV and AIDS in developing countries is at a crossroads. The dream of future generations freed from the epidemic is running up against an era ...

HIV & AIDS created May 21, 2013 | popularity not rated yet | comments 0


Slowing the aging process—only with antibiotics

Swiss scientists reveal the mechanism responsible for aging hidden deep within mitochondria—and dramatically slow it down in worms by administering antibiotics to the young.

Researchers complete largest genetic sequencing study of human disease

Researchers from Queen Mary, University of London have led the largest sequencing study of human disease to date, investigating the genetic basis of six autoimmune diseases.

Brain can be trained in compassion, study shows

Until now, little was scientifically known about the human potential to cultivate compassion—the emotional state of caring for people who are suffering in a way that motivates altruistic behavior.

Having both migraines, depression may mean smaller brain

(HealthDay)—Migraines and depression can each cause a great deal of suffering, but new research indicates the combination of the two may be linked to something else entirely—a smaller brain.

Novel approach for influenza vaccination shows promise in early animal testing

A new approach for immunizing against influenza elicited a more potent immune response and broader protection than the currently licensed seasonal influenza vaccines when tested in mice and ferrets. The vaccine ...

Enzyme-activating antibodies revealed as marker for most severe form of rheumatoid arthritis

In a series of lab experiments designed to unravel the workings of a key enzyme widely considered a possible trigger of rheumatoid arthritis, researchers at Johns Hopkins have found that in the most severe ...